Literature DB >> 21434799

Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.

Jan Poolman1, Ray Borrow.   

Abstract

Hyporesponsiveness (immune tolerance) follows vaccination with meningococcal polysaccharide and many pneumococcal polysaccharide serotypes. Hyporesponsiveness after Haemophilus influenzae type b polysaccharide vaccination has not been directly observed, but may follow exposure during disease in some individuals. Use of currently licensed conjugate vaccines has not been associated with hyporesponsiveness to date, with the possible exception of pneumococcal serotype 3. Introduction of polysaccharide vaccines anywhere into a conjugate vaccination schedule may result in reduced immune responses on subsequent exposure. This review of vaccine-induced hyporesponsiveness and its potential clinical implications considers recent evidence suggesting that hyporesponsiveness may occur for specific components of combined conjugate vaccines, such as pneumococcal serotype 3. These data have implications for the development of new multivalent vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434799     DOI: 10.1586/erv.11.8

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  49 in total

1.  [Pneumococcus vaccination in immunosuppressed patients: current recommendations].

Authors:  A Krause; K Krüger
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 2.  B-1 lymphocytes in mice and nonhuman primates.

Authors:  Karen M Haas
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

3.  Splenectomy: reducing the risk of infection.

Authors:  Joanne M Langley; Shelly McNeil
Journal:  CMAJ       Date:  2012-11-20       Impact factor: 8.262

Review 4.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

5.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

6.  B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool.

Authors:  Christina A Daly; M Ariel Spurrier; Jamie E Jennings-Gee; Karen M Haas
Journal:  J Immunol       Date:  2020-09-25       Impact factor: 5.422

7.  Anti-Pneumococcal Vaccine-Induced Cellular Immune Responses in Post-Traumatic Splenectomized Individuals.

Authors:  Djursun Karasartova; Umut Gazi; Ozgur Tosun; Ayse S Gureser; Ibrahim T Sahiner; Mete Dolapci; Aysegul T Ozkan
Journal:  J Clin Immunol       Date:  2017-05-09       Impact factor: 8.317

8.  An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Authors:  James P Phipps; Karen M Haas
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

9.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

10.  [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.